CNX Therapeutics Acquires Global Sativex Business from Jazz
CNX Therapeutics has acquired the global Sativex® (nabiximols) business from Jazz Pharmaceuticals, reinforcing its position in the central nervous system (CNS) therapeutic space.
The transaction, completed on 31 October 2025, includes the transfer of marketing authorisations, commercial partnerships and manufacturing arrangements, signalling a comprehensive handover of one of the best-known cannabinoid medicines in neurology.
A strategic fit for specialist CNS growth
CNX Therapeutics said the deal strengthens its role as a provider of specialist CNS medicines across European markets and aligns squarely with its strategy to grow through focused acquisitions in areas where it can make a meaningful difference for patients.
Company leadership highlighted Sativex’s status as the first plant-derived cannabinoid medicine approved by a medicines regulator as a cornerstone of the portfolio’s clinical credibility and commercial potential.
Indication and reach
Sativex is approved in the European Union, the United Kingdom and other international markets for adult patients with moderate to severe spasticity due to multiple sclerosis (MS) who have not responded adequately to other anti-spasticity treatments and who show clinically significant improvement during an initial trial.
Its established label and clinician familiarity provide CNX with a strong platform for sustained engagement across neurology centres and MS pathways.
Continuity of supply and support
Ensuring seamless access is central to the transition plan. CNX Therapeutics has committed to continuity of supply and support for both patients and healthcare professionals over the long term.
Jazz Pharmaceuticals will continue to support the handover via a Transition Service Agreement, helping maintain operational stability as systems, partnerships and manufacturing frameworks are transferred.
Leveraging existing CNS infrastructure
CNX’s corporate development team underscored that the acquisition is a strategic fit for the company’s established CNS infrastructure and therapeutic expertise.
With an experienced European specialty footprint, CNX plans to integrate Sativex into its commercial and medical operations with minimal disruption, prioritising seamless continuity of access for the patients who rely on the medicine.
What the deal includes
Beyond the asset itself, the transaction encompasses the marketing authorisations necessary to commercialise Sativex in approved territories, the commercial partnerships that sustain market presence, and the manufacturing arrangements that underpin reliable supply.
Together, these elements equip CNX to steward the brand and support clinical practice without interruption.
Looking ahead
The acquisition represents a key step in CNX Therapeutics’ expansion strategy, focused on improving access to essential medicines for people living with chronic neurological conditions.
By combining Sativex’s proven therapeutic role in MS spasticity with CNX’s specialist capabilities, the company is positioned to deepen its engagement with European neurology networks and advance its broader CNS portfolio.
Conclusion
With the global Sativex business now under its stewardship, CNX Therapeutics has added a clinically established, regulator-approved cannabinoid therapy to its CNS stable – backed by a transition plan designed to keep patients and clinicians fully supported.
The result is a deal that blends strategic focus with practical continuity: a stronger European specialty portfolio for CNX and a clear commitment to safeguarding access for MS patients who benefit from Sativex.
News Credits: CNX Therapeutics acquires Sativex from Jazz Pharmaceuticals
Things you may also like: